ABSTRACT
Chronic hepatitis B and C affect 520 million people worldwide, and are a major cause of chronic liver disease and of mortality, despite the efficacy of the vaccine. Hepatitis B and C: Management and Treatment second edition provides a practical explanation of the natural history and management of the disease, and examines the benefits of the most recent drugs, and their effects, whether used in isolation or as part of a combination therapy. This second edition expands the coverage of treatment of various difficult-to-treat patients and will be a welcome guide to the physician in both clinical decision-making and in explaining the benefits and side-effects to the patient.
TABLE OF CONTENTS
part I|1 pages
Hepatitis C
chapter 1|3 pages
Natural History of Hepatitis C: Epidemiology
chapter 2|9 pages
Natural History of Hepatitis C: Hepatic Manifestations
chapter 4|19 pages
Management Protocols in Chronic Hepatitis C
chapter 5|4 pages
Management of Relapsers and Nonresponders—Maintenance Therapy
chapter 6|4 pages
Management of Patients with Cirrhosis
chapter 7|2 pages
Management of Patients Coinfected by HCV and HIV
chapter 8|2 pages
Management of HCV Infection After Liver Transplantation
chapter 9|1 pages
Management of Patients with Renal Disease
chapter 10|2 pages
Other Difficult-to-treat Populations
chapter 11|6 pages
Safety of Interferon, Pegylated Interferon (PEG-IFN) and Ribavirin
chapter 12|2 pages
Who Needs to be Treated and How to Explain the Goals to the Patient
chapter 13|3 pages
What is the cost-effectiveness of combination regimes?
chapter 14|2 pages
Management of Acute Hepatitis C
chapter 15|3 pages
Practical Guidelines for the Management of Hepatitis C
chapter 16|4 pages
New Drugs in Development
chapter |7 pages
References
part II|1 pages
Hepatitis B
chapter 17|4 pages
Natural History of Hepatitis B: Epidemiology
chapter 18|9 pages
Natural History of Hepatitis B: Hepatic Manifestations
chapter 20|2 pages
Goal of Treatment in Chronic Hepatitis B
chapter 21|4 pages
Efficacy of Interferon and Pegylated Interferon (PEG-IFN)
chapter 22|7 pages
Efficacy of Lamivudine
chapter 24|1 pages
Safety of Lamivudine
chapter 25|3 pages
Efficacy of Adefovir
chapter 26|2 pages
Safety of Adefovir
chapter 28|1 pages
New Drugs in Development
chapter 29|3 pages
Who Needs to be Treated and How to Explain the Goals to the Patient
chapter 30|1 pages
Management of Relapsers and Nonresponders
chapter 31|1 pages
Management of Patients Coinfected by HBV and HIV
chapter 32|1 pages
Management of Transplanted Patients Chronically Infected by HBV
chapter 33|1 pages
Cost-effectiveness of Treatment
chapter |6 pages
References
part III|1 pages
Biochemical Markers: An Alternative to Liver Biopsies